Literature DB >> 12576391

Chylothorax in lymphangioleiomyomatosis.

Jay H Ryu1, Clint H Doerr, Susan D Fisher, Eric J Olson, Steven A Sahn.   

Abstract

STUDY
OBJECTIVE: Pulmonary lymphangioleiomyomatosis (LAM) is a rare, serious disorder characterized by proliferation of abnormal smooth-muscle cells and affects almost exclusively women of childbearing age. Optimal management of chylothorax, a well-recognized complication of LAM, in these patients has not been defined. This study was performed to characterize the clinical course and identify appropriate management options for chylothorax occurring in patients with LAM.
DESIGN: Identification and retrospective review of available medical records on patients with LAM and chylothorax.
SETTING: Tertiary-referral medical center. PATIENTS: All patients with LAM seen at Mayo Clinic, Rochester, MN, from January 1, 1976, to December 31, 2000. INTERVENTION: None. MEASUREMENT AND
RESULTS: Eight of 79 patients (10.1%) with LAM had chylothorax. All were women aged 33 to 51 years, and four patients had underlying tuberous sclerosis complex. These eight women represented 3.5% of the 229 patients with chylothorax seen over this 25-year period at Mayo Clinic Rochester. Six patients had unilateral pleural effusion and two patients had bilateral effusions at initial presentation. The size of the chylothorax varied and was not necessarily progressive. Management of chylothorax ranged from thoracentesis only to thoracotomy with thoracic duct ligation and parietal pleurectomy. When needed, pleurodesis by instillation of sclerosing agents or parietal pleurectomy appeared to be effective in controlling chylothorax.
CONCLUSIONS: Chylothorax occurring in patients with LAM has a variable clinical course. Although pleurodesis with or without thoracic duct ligation appears to be effective in controlling intractable chylothorax, less invasive treatments such as thoracentesis or observation may suffice in some cases. Management of chylothorax in patients with LAM should be individualized depending on the size and clinical effects of the chylous pleural effusion, as well as comorbid factors and local expertise.

Entities:  

Mesh:

Year:  2003        PMID: 12576391     DOI: 10.1378/chest.123.2.623

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

Review 1.  Lymphangioleiomyomatosis.

Authors:  Francis X McCormack
Journal:  MedGenMed       Date:  2006-01-18

2.  Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Thomas Shawker; Connie G Glasgow; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

3.  Bilateral spontaneous persistent open pneumothorax with chylothorax.

Authors:  Rumi Khajotia; Sree Raman
Journal:  Can Fam Physician       Date:  2012-07       Impact factor: 3.275

Review 4.  Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.

Authors:  Felipe Mussi von Ranke; Gláucia Zanetti; Jorge Luiz Pereira e Silva; Cesar Augusto Araujo Neto; Myrna C B Godoy; Carolina A Souza; Alexandre Dias Mançano; Arthur Soares Souza; Dante Luiz Escuissato; Bruno Hochhegger; Edson Marchiori
Journal:  Lung       Date:  2015-06-24       Impact factor: 2.584

Review 5.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

6.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

7.  Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literature.

Authors:  Kai Wu; Hui-Yu Lu
Journal:  Exp Ther Med       Date:  2015-03-31       Impact factor: 2.447

8.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

Review 9.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

Review 10.  Lymphatic involvement in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo M Taveira-Dasilva; Thomas N Darling; Joel Moss
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.